KURA
Kura Oncology, Inc.NASDAQHealthcare$8.61+3.24%ClosedMarket Cap: $760.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.35
P/S
11.27
EV/EBITDA
-2.18
DCF Value
$23.41
FCF Yield
-9.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
94.6%
Operating Margin
-449.9%
Net Margin
-412.9%
ROE
-102.6%
ROA
-37.7%
ROIC
-48.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $17.3M | 97.3% | $-86.3M | $-81.0M | $-0.92 | — |
| FY 2025 | $67.5M | 99.9% | $-303.6M | $-278.7M | $-3.18 | — |
| Q3 2025 | $20.8M | 84.5% | $-80.0M | $-74.1M | $-0.85 | — |
| Q2 2025 | $15.3M | 100.0% | $-72.7M | $-66.1M | $-0.75 | — |
| Q1 2025 | $14.1M | 100.0% | $-64.7M | $-57.4M | $-0.66 | — |
| Q4 2024 | $53.9M | 100.0% | $-22.5M | $-19.2M | $-0.22 | — |
| FY 2024 | $53.9M | 100.0% | $-193.2M | $-174.0M | $-2.02 | — |
| Q3 2024 | $0.00 | NaN% | $-59.9M | $-54.4M | $-0.63 | — |
| Q2 2024 | $0.00 | -Infinity% | $-56.4M | $-50.8M | $-0.59 | — |
| Q1 2024 | $0.00 | -Infinity% | $-54.5M | $-49.5M | $-0.59 | — |
| Q4 2023 | $0.00 | -Infinity% | $-46.8M | $-42.8M | $-0.55 | — |
| FY 2023 | $0.00 | -Infinity% | $-165.8M | $-152.6M | $-2.08 | — |